MYC is dysregulated in nearly 70% of human cancers, where it influences a vast network of biological processes including cell cycle control, metabolism, apoptosis, angiogenesis, and immune evasion.

University of North Carolina Lineberger Comprehensive Cancer Center researchers have developed a "two-in-one" molecule that can simultaneously turn off two notoriously difficult-to-target ...